Explaining Resistance to CAR T Cells
- PMID: 29769184
- DOI: 10.1158/2159-8290.CD-NB2018-065
Explaining Resistance to CAR T Cells
Abstract
A new study reveals several attributes of T cells from patients with chronic lymphocytic leukemia who respond to CAR T-cell therapy. The patients' T cells show increased expression of memory-related genes and high activity of STAT3, which promotes memory cell differentiation. The researchers also found that patients who underwent complete remission have certain CD8+ T cells.
©2018 American Association for Cancer Research.
Comment on
-
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia.Nat Med. 2018 May;24(5):563-571. doi: 10.1038/s41591-018-0010-1. Epub 2018 Apr 30. Nat Med. 2018. PMID: 29713085 Free PMC article.
Similar articles
-
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia.Nat Med. 2018 May;24(5):563-571. doi: 10.1038/s41591-018-0010-1. Epub 2018 Apr 30. Nat Med. 2018. PMID: 29713085 Free PMC article.
-
Only the best CAR T cells.Nat Rev Clin Oncol. 2018 Jul;15(7):402-403. doi: 10.1038/s41571-018-0039-6. Nat Rev Clin Oncol. 2018. PMID: 29760506 No abstract available.
-
Accelerating chimeric antigen receptor therapy in chronic lymphocytic leukemia: The development and challenges of chimeric antigen receptor T-cell therapy for chronic lymphocytic leukemia.Am J Hematol. 2019 May;94(S1):S10-S17. doi: 10.1002/ajh.25457. Epub 2019 Mar 23. Am J Hematol. 2019. PMID: 30861173 Review.
-
Insights into Chimeric Antigen Receptor Therapy for Chronic Lymphoblastic Leukemia.Trends Mol Med. 2018 Sep;24(9):729-731. doi: 10.1016/j.molmed.2018.06.007. Epub 2018 Jul 4. Trends Mol Med. 2018. PMID: 30149852
-
Cell therapy of chronic lymphocytic leukaemia: Transplants and chimeric antigen receptor (CAR)-T cells.Blood Rev. 2022 Jan;51:100884. doi: 10.1016/j.blre.2021.100884. Epub 2021 Sep 1. Blood Rev. 2022. PMID: 34489116 Review.
Cited by
-
Gene modification strategies for next-generation CAR T cells against solid cancers.J Hematol Oncol. 2020 May 18;13(1):54. doi: 10.1186/s13045-020-00890-6. J Hematol Oncol. 2020. PMID: 32423475 Free PMC article. Review.
-
Clinical cancer immunotherapy: Current progress and prospects.Front Immunol. 2022 Oct 11;13:961805. doi: 10.3389/fimmu.2022.961805. eCollection 2022. Front Immunol. 2022. PMID: 36304470 Free PMC article. Review.
-
Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors: The Past and the Future.J Immunother Precis Oncol. 2022 Dec 28;6(1):19-30. doi: 10.36401/JIPO-22-7. eCollection 2023 Feb. J Immunother Precis Oncol. 2022. PMID: 36751657 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous